Acute Care Utilization After Recovery Coaching Linkage During Substance-Related Inpatient Admission: Results of Two Randomized Controlled Trials

Julia A. Cupp, MD1, Kaileigh A. Byrne, PhD2, Kristin Herbert, BS3, and Prerana J. Roth, MD1

1Prisma Health-Upstate, Greenville, USA; 2Clemson University, Clemson, USA; 3University of South Carolina School of Medicine-Greenville, Greenville, USA.

BACKGROUND: For patients with substance use disorder (SUD), a peer recovery coach (PRC) intervention increases engagement in recovery services; effective support services interventions have occasionally demonstrated cost savings through decreased acute care utilization.

OBJECTIVE: Examine effect of PRCs on acute care utilization.

DESIGN: Combined results of 2 parallel 1:1 randomized controlled trials.

PARTICIPANTS: Inpatient adults with substance use disorder

INTERVENTIONS: Inpatient PRC linkage and follow-up contact for 6 months vs usual care (providing contact information for SUD resources and PRCs)

MAIN MEASURES: Acute care encounters (emergency and inpatient) 6 months before and after enrollment; encounters type by primary diagnosis code category (mental/behavioral vs medical); 30-day readmissions with Lace+ readmission risk scores.

KEY RESULTS: A total of 193 patients were randomized: 95 PRC; 98 control. In the PRC intervention, 66 patients had a pre-enrollment acute care encounter and 56 had an encounter post-enrollment, compared to the control group with 59 pre- and 62 post-enrollment (odds ratio [OR] = −0.79, P = 0.11); there was no significant effect for sub-groups by encounter location (emergency vs inpatient). There was a significant decrease in mental/behavioral ED visits (PRC: pre-enrollment 17 vs post-enrollment 10; control: pre-enrollment 13 vs post-enrollment 16 (OR = −2.62, P = 0.02)) but not mental/behavioral inpatient encounters or medical emergency or inpatient encounters. There was no significant difference in 30-day readmissions corrected for Lace+ scores (15.8% PRC vs 17.3% control, OR = 0.19, P = 0.65).

CONCLUSIONS: PRCs did not decrease overall acute care utilization but may decrease emergency encounters related to substance use.

TRIAL REGISTRATION: ClinicalTrials.gov (NCT04098601, NCT04098614)

INTRODUCTION

Patients with substance use disorder (SUD) use acute care services at higher rates than patients without SUD: the diagnosis is associated with a 4 times greater rate of emergency department (ED) visits, 7 times greater rate of hospital admission, and double the rate of recurrent acute care utilization after hospital discharge. Early observational studies of acute care utilization suggested that support services, such as case management (CM) programs, for the high-utilizer population would decrease utilization of high-cost acute care. Their effect size was overestimated by the observational studies’ vulnerability to regression-to-the-mean. A conclusively positive effect has not been replicated in the few available randomized controlled trials (RCTs). The most recent trial randomized 486 high-risk patients to a case management intervention (409 to control) and found no significant reduction in subsequent acute care utilization. Studies specific to patients with SUD have also found mixed results from support services interventions on acute care utilization and merit further research.

These support services are heterogeneous. Inpatient CM most often focuses on discharge planning and follows a brokerage model limited to assessment of needs and assistance with resource acquisition.
adopt smaller caseloads to enable active outreach, deeper relationships, and broader services. Meta-analyses on CM interventions indicate more reliable favorability for treatment-related outcomes, such as linkage and retention, than for substance use, although these studies are often limited by heterogeneity and risk of bias.\textsuperscript{17-21} Peer recovery support services extend relationship-based community support beyond the confines of professional services.\textsuperscript{22,23} Their impact on acute care utilization is unknown.\textsuperscript{24}

Peer recovery support services are delivered by a peer recovery coach (PRC). A PRC is defined here as: an individual in active recovery for a minimum of 1 year, trained and certified as a Peer Support Specialist.\textsuperscript{25} The PRC uses assertive community engagement techniques to guide the patient through the recovery process with regular, personal coaching and connection to recovery resources. PRCs use their combined experience and training to provide reliable socioemotional, instrumental, and informational support over an extended time period. PRCs differ from other support services because PRCs represent non-clinical peer mentors with shared substance-related experience and can be a direct confidante (Supplement).\textsuperscript{25,26}

Our institution has recently invested in having PRCs physically present in the ED, but resources were insufficient to make PRCs available for inpatients as well. Anticipating beneficial effects of expanding PRC services to the inpatient population, we recently conducted 2 RCTs evaluating the intervention of establishing a PRC relationship during a SUD-related inpatient admission. The first study had favorable results for psychosocial outcomes: inpatient linkage to PRC successfully increased engagement in recovery services\textsuperscript{27}; the second is under analysis. These datasets provided an opportunity to rigorously evaluate the intervention’s effect on acute care utilization in a high-risk group. We predicted that the intervention would lead to decreased acute care utilization.

**METHODS**

Two consecutive investigator-initiated, single-center studies at Greenville Memorial Hospital in Greenville, SC, recruited patients for evaluation of the same PRC intervention from April 2018 to June 2019 (study 1) and July 2019 to March 2020 (study 2); both studies were approved by the institutional review board at Prisma Health and registered on ClinicalTrials.gov (NCT04098601 and NCT04098614). Patients with SUD were identified by their primary provider and referred to the study team. No changes were made to eligibility during each study period but 4 exclusion criteria were added for study 2 after study 1 was found to have limitations of losing patients to follow-up and too few patients in the cocaine-only and benzodiazepine-only group for sub-analyses:

*Inclusion criteria for both studies:*
1) Age $\geq$ 18 years
2) Admitted to internal medicine or receiving infectious disease consultation
3) Identified by healthcare provider as having SUD

*Exclusion criteria for both studies:*
1) Age < 18 years
2) Unable to provide informed consent (intubation, confusion) during hospitalization
3) Admitted for cannabis use only
4) Pregnant

*Additional exclusion criteria for study 2:*
5) Age $>$ 60 years
6) Admitted for cocaine use only or benzodiazepine use only (to decrease heterogeneity)
7) Lack of at least 1 verifiable point of contact for follow-ups (phone, email, etc.)
8) Non-English speaker

Parallel 1:1 allocation was performed with allocation concealment maintained using Redcap (Supplement). The primary provider was not blinded to the study condition.

**Intervention and Control Conditions**

Patients allocated to the intervention received a bedside visit from a PRC within 24 h of consent, during their baseline hospitalization, without the patient needing to do anything to initiate contact. The PRC contacted the patient at least twice weekly in a persistent but respectful patient-centered approach for the 6-month study duration. Following the March 2020 pandemic onset, communication transitioned from face-to-face to telephone contact.

At the time of this study, this hospital did not have an inpatient addiction consultation service. Inpatient psychiatry consultation was not routinely called for treatment of SUD, generally considered the responsibility of the primary service. The standard of care involved a social work consult through which the patient was provided a type-written list of SUD resources in the local area. The list included PRCs: patients allocated to the control had a telephone in their room and were given the PRC group’s phone number; the patient was independently responsible for initiating contact. Given that both intervention and control groups were given access to PRCs, the subjects were not aware of the alternative condition nor whether they were considered intervention or control.

**Outcome Measures**

The primary outcome was number of acute care encounters, and proportion of patients with an acute care encounter, during the 6 months after study enrollment, as compared to during the preceding 6 months. Encounter sub-groups included encounter location (ED or inpatient).
and primary type of visit. The primary outcome was assessed for study 1 upon completion of study 1 and assessed for study 2 and combined studies 1 + 2 upon completion of study 2.

The Medicare quality metric 30-day readmissions was added after analysis of study 1 showed nonsignificant change in overall utilization. This was first assessed for study 1 + study 2 upon completion of study 2. The discharge date from the consent admission began the 30-day return period for each participant, even if that discharge was against medical advice (AMA). Lace+30-day readmission risk scores were used to incorporate the following predictors to correct for readmission risk: age, sex, comorbidities, prior utilization, admission acuity, and length of stay.

**Data Sources and Coding**

The data collector and outcome assessor remained blinded to group allocation for all study activities.

Hospital system administrative records were supplemented by individual chart review to collect: encounters for each subject for the time period 6 months preceding and 6 months following the subject’s date of consent; encounter locations; encounter diagnosis codes; hospital disposition location; LACE+ score upon enrollment; encounter discharge date as calculated by the electronic medical record. Encounter location was defined as ED if the patient remained in the ED and was discharged by an emergency medicine physician and defined as inpatient if the patient received care in the inpatient unit and was discharged by an inpatient service. Encounters linked by hospital transfers for ongoing acute medical care (ED to inpatient or from one inpatient medical hospital to another) were consolidated into a single inpatient encounter. With these methods, the ED and inpatient encounter subsets are mutually exclusive and collectively exhaustive subsets of the full set of acute care encounters. The encounter ended when the patient discharged to home or transferred to external sites.

Primary type of visit was assigned by mapping the visit’s primary diagnosis billing code via AHRQ’s Clinical Classifications Software Refined “default diagnosis” to either “mental/behavioral disorders” (MBD, which includes substance-related diagnoses) or any other category (medical). This coding was chosen based on prior studies’ interventions demonstrating stronger effects on utilization related to psychiatric diagnoses than medical.

Study 2’s consent form included collection of both the primary hospital system and outside hospital data, increasing record availability to 97% of the 25-mile radius hospital beds (Supplement).

At 30, 60, 90, and 180 days post-enrollment, a blinded research team member contacted all participants for a phone or email survey about their involvement with recovery programs.

**Statistical Analysis**

Demographic comparisons were performed using independent samples t-tests and chi-squared tests.

ED encounters, inpatient encounters, and total acute care encounters (ED + inpatient) were evaluated as (1) continuous variables and (2) dichotomized 0 vs 1+ ED/inpatient/either encounters. Predictor variables for all models included Condition (Intervention vs. Control) and Time (Pre- vs. Post-Enrollment). All models were adjusted for death. Generalized linear mixed-effects models (GLMM) assuming a binomial outcome distribution and logit link function were applied to the binary outcome measures (patients who either did or did not have an ED visit, inpatient admission, etc. during the pre- and post-consent time periods). Linear mixed-effects models (LMM) were applied to continuous outcome measures (the total number of ED visits, inpatient admissions, etc. during the pre- and post-consent time periods). These calculations were performed on study 1 upon its completion and the same analytical methods were applied to study 2 upon its completion, and then to the combined study 1 + study 2. Post hoc sub-group analyses by SUD group were performed.

A GLMM was performed for 30-day inpatient readmission status using Condition (Intervention vs. Control) and LACE scores as predictors. Tests were two-tailed.

The sample size was fixed: the original primary outcome of study 1 was to evaluate the effect of the PRC intervention on treatment engagement, for which a priori power analysis suggested a goal enrollment of 100 patients; power analysis for study 2 suggested a goal of 120 patients to evaluate how specific personal and neurocognitive moderators influence the effect of the intervention. This provided an anticipated 220 subjects for the acute care utilization analysis. This number was comparable to the highest-quality acute care utilization studies available at the time of protocol development finding significant results using 250 participants while achieving an effect size near 50% reduction in ED utilization.

**RESULTS**

Study 1 successfully enrolled the pre-defined 100 patients. Study 2 enrollment ended early (96 of intended 120 participants) upon implementation of strict hospital access restrictions March 2020 due to COVID-19 (PRCs are not hospital employees).

Given that interim analysis occurred between study 1 and study 2, figures and tables provide all results reported for the studies separately and combined. Of 202 patients who consented and received randomization, 193 completed enrollment, were discharged from the consent hospitalization alive, and were included in analysis (Fig. 1). The mean age was 42 years (SD = 10.3) and the most frequent substance used was alcohol with 45% having alcohol use disorder only. Further demographics are provided in Table 1 and supplement. Demographics between the studies were similar except...
the following: study 2 had significantly more patients predominantly using methamphetamine (17% vs 4%, \( P = 0.003 \)) and fewer patients with private insurance (9.6% vs 20.2%, \( P = 0.04 \)).

All analyses utilized an intention-to-treat approach. Of the 98 control participants, only 2 established care with a PRC. Of intervention participants, 100% established care with a PRC by study design; 77.9% remained in contact with their PRC at least once every other month throughout the 6-month study period. Average frequency of contact across all participants in the intervention condition was 6.57 contacts per month (SD = 5.59).

**Primary Outcome: Total Acute Care Encounters**

The intervention provided a favorable but not statistically significant decrease in the proportion of patients with any acute care encounters and no significant improvement in proportion of patients with any ED-only encounters or inpatient-only encounters pre- vs post-intervention. Table 2 shows results for the primary outcome as a dichotomous variable.

The intervention provided no significant difference in change in number of total acute care encounters from the 6 months pre-enrollment to the 6 months post-enrollment (OR = −0.16, \( P = 0.61 \)). Between intervention and control, there was no significant change in number of pre- and post-enrollment ED-only encounters (OR = −0.23, \( P = 0.39 \)), nor in inpatient-only encounters (OR = 0.07, \( P = 0.73 \)). Over the 12-month period of study participation, 46 subjects (24 intervention; 22 control) had 5 or more acute care encounters, meeting the SC Public Health Institute definition of “frequent user.” Table 3 shows the results for the primary outcome as a continuous variable.

**Primary Outcome: Mental and Behavioral Disorder-Related Acute Care Encounters**

The intervention provided no significant difference in change in total number of MBD-related encounters (OR = −0.19, \( P = 0.17 \)) or proportion of patients with an MBD-related encounter (OR = −1.74, \( P = 0.08 \)). However, the intervention did show a significant decrease in the subgroup of dichotomized ED encounters primarily coded as MBD. Analysis of the combined study results indicated that the percentage of patients in the intervention group having MBD ED visits decreased from 17.9% (SD = 38.5, 95% CI: 10.0–25.7) in the 6 months pre-enrollment to 10.5% (SD = 30.85, 95% CI: 4.2–16.8) in the 6 months post-enrollment. For the control group, these percentages were 13.3% pre-enrollment and 16.3% post-enrollment (OR = −2.62, \( P = 0.022 \)). When the studies were
analyzed individually, this benefit was statistically significant for study 1 (OR = −4.05, P = 0.04) but did not reach significance for study 2 (OR = −1.28, P = 0.33) (Fig. 2). When evaluated as a continuous variable, number of MBD ED encounters pre- vs post-enrollment showed a favorable trend for the intervention but did not reach statistical significance (OR = −0.24, P = 0.06 for the combined study results). There was no statistically significant effect demonstrated for the intervention on evaluation of MBD inpatient encounters (neither as dichotomous nor continuous variables, Tables 2 and 3).

**Secondary Outcomes**

A 30-day readmission from the consent encounter occurred in 16.6% percent of total subjects (17 in the control condition; 15 in the intervention; OR = 0.19, P = 0.65) (Table 2). There were 5 AMA discharges from the consent encounter (3 in the control condition; 2 in the intervention); post-hoc exclusion of AMA discharges did not significantly change these outcomes. No significant effects for the primary outcomes were observed for any substance-type sub-groups (Supplement).

**Table 1 Demographic Variables as Reported or Calculated at Time of Consent, Combined* Sample**

| Variable                        | Total (N = 193) | Intervention (N = 95) | Control (N = 98) | p value |
|--------------------------------|----------------|-----------------------|------------------|---------|
| **Gender**                      |                |                       |                  |         |
| Men (n, %)                      | 115 (59.6%)    | 60 (63.2%)            | 55 (56.1%)       | 0.32    |
| Age (mean ± SD)                 | 41.74 (± 10.30)| 41.73 (± 10.70)       | 41.74 (± 9.96)   | 0.99    |
| Years of education              | 12.04 (± 2.12) | 12.00 (± 2.17)        | 12.08 (± 2.09)   | 0.79    |
| Years of SUD                    | 14.72 (± 11.09)| 15.30 (± 12.25)       | 14.16 (± 9.89)   | 0.48    |
| Days of use in past month       | 15.68 (± 11.56)| 16.68 (± 11.63)       | 14.71 (± 11.48)  | 0.24    |
| LACE+ Score                     | 52.82 (± 19.38)| 53.67 (± 19.25)       | 52.00 (± 19.58)  | 0.55    |
| **Race**                        |                |                       |                  |         |
| Caucasian                       | 154 (79.8%)    | 78 (82.1%)            | 76 (77.6%)       | 0.87    |
| African American                | 30 (15.5%)     | 12 (12.6%)            | 18 (18.4%)       | 0.27    |
| Hispanic                        | 5 (2.6%)       | 3 (3.2%)              | 3 (3.1%)         | 0.66    |
| Other                           | 4 (2.1%)       | 3 (3.2%)              | 1 (1.0%)         | n/a     |
| **Employment status**           |                |                       |                  |         |
| Full-time                       | 38 (19.7%)     | 21 (22.1%)            | 17 (17.3%)       | 0.52    |
| Part-time                       | 13 (6.7%)      | 7 (7.4%)              | 6 (6.1%)         | 0.78    |
| Unemployed                      | 86 (44.6%)     | 40 (42.1%)            | 46 (46.9%)       | 0.52    |
| Disabled                        | 47 (24.4%)     | 24 (25.3%)            | 23 (23.5%)       | 0.88    |
| Other                           | 8 (4.1%)       | 2 (2.1%)              | 6 (6.1%)         | 0.16    |
| **Insurance status**            |                |                       |                  |         |
| No insurance                    | 107 (55.4%)    | 48 (50.5%)            | 59 (60.2%)       | 0.29    |
| Private                         | 29 (15.0%)     | 17 (17.9%)            | 12 (12.2%)       | 0.35    |
| Medicare*                       | 20 (10.4%)     | 11 (11.6%)            | 9 (9.2%)         | 0.66    |
| Medicaid*                       | 34 (17.6%)     | 16 (16.8%)            | 18 (18.4%)       | 0.73    |
| Medicare/Medicaid*              | 50 (25.9%)     | 25 (26.3%)            | 25 (25.5%)       | 1       |
| Other (VA., etc.)               | 7 (3.6%)       | 5 (5.3%)              | 2 (2.0%)         | 0.26    |
| **Substance used (self-reported)** |             |                       |                  |         |
| Alcohol                         | 87 (45.1%)     | 46 (48.4%)            | 41 (41.8%)       | 0.59    |
| Opioids                         | 22 (11.4%)     | 12 (12.6%)            | 10 (10.2%)       | 0.67    |
| Methamphetamine                 | 20 (10.4%)     | 9 (9.5%)              | 11 (11.2%)       | 0.66    |
| Cocaine                         | 6 (3.1%)       | 2 (2.1%)              | 4 (4.2%)         | 0.41    |
| Polysubstance                   | 58 (30.1%)     | 26 (27.4%)            | 32 (32.7%)       | 0.43    |
| 3+ substances                   | 21 (10.9%)     | 11 (11.6%)            | 10 (10.2%)       | 0.76    |
| Opiate/meth                     | 21 (10.9%)     | 11 (11.6%)            | 10 (10.2%)       | 0.76    |
| Alcohol/cocaine                 | 7 (3.6%)       | 1 (1.1%)              | 6 (6.1%)         | 0.06    |
| Alcohol/meth                    | 3 (1.6%)       | 1 (1.1%)              | 2 (2.0%)         | 0.25    |
| Alcohol/opiate                  | 3 (1.6%)       | 1 (2.1%)              | 2 (1.0%)         | -       |
| **Primary diagnosis category frequency at consent hospitalization** | |                       |                  |         |
| Alcohol-related disorders       | 38 (19.7%)     | 23 (24.2%)            | 15 (15.3%)       | 0.19    |
| Septicemia                      | 27 (14.0%)     | 15 (15.8%)            | 12 (12.2%)       | 0.56    |
| Suicidal ideation               | 11 (5.7%)      | 4 (4.2%)              | 7 (7.1%)         | 0.37    |

*Demographics reported separately for study 1 and study 2 in supplement tables
**Gender as self-reported. No participants chose non-binary; number of women is difference from total
*Four participants had both Medicare and Medicaid insurance

**DISCUSSION**

In summary, a PRC intervention for patients with SUD did not significantly decrease overall acute care utilization but did decrease MBD ED visits over a 6-month follow-up period. The decrease in MBD ED visits was most pronounced in study 1 and remained significant when study results were combined. Study 1 and study 2 were conducted in continuing series and intended to produce homogenous results, but study 2 by itself did not show a significant decrease in MBD ED visits. Differences between the studies may be instructive. Study 2 had more patients using methamphetamines. Moreover, on March 11, 2020, the World Health Organization declared COVID-19 a pandemic; study 1 was already completed, but study 2 only had 15 patients who had completed their 6-month follow-up by that date. Across the country, ED visits dropped by 42%. PRC visits went from face-to-face to telephone. The pandemic likely had 2 diminishing effects on study 2: virtual PRC sessions may be less effective than in-person sessions; overall utilization may have decreased beyond any marginal benefit from the PRC intervention. It was encouraging that,
Table 2: Acute Care Utilization Measured as Binary Events

| Study | Intervention (n = 49) | Control (n = 50) | OR | p value |
|-------|-----------------------|------------------|----|---------|
|       | Pre                   |                  |    |         |
|       | Post                  |                  |    |         |
| Pre, including OSH | 34 (69.4%)          | 28 (56.0%)      | -0.86 | 0.19   |
| Post, including OSH | 27 (55.1%)          | 29 (58.0%)      |    |         |
| Patients with an inpatient admission, n (%) |                  |                  |    |         |
| Pre  | 11 (22.4%)            | 17 (34.0%)      | 0.58 | 0.40   |
| Post | 16 (32.7%)            | 18 (36.0%)      |    |         |
| Pre, including OSH | 19 (41.3%)          | 15 (31.3%)      | -1.11 | 0.09   |
| Post, including OSH | 20 (43.5%)          | 25 (52.1%)      |    |         |
| Patients with an ED visit, n (%) |                  |                  |    |         |
| Pre  | 30 (61.2%)            | 23 (46.0%)      | -0.76 | 0.20   |
| Post | 21 (42.9%)            | 22 (44.0%)      |    |         |
| Pre, including OSH | 26 (56.5%)          | 27 (56.3%)      | 0.10 | 0.86   |
| Post, including OSH | 21 (45.7%)          | 23 (47.9%)      |    |         |
| Patients with an MBD acute encounter, n (%) |                  |                  |    |         |
| Pre  | 11 (22.4%)            | 5 (10.0%)       | -2.45 | 0.07   |
| Post | 8 (16.3%)             | 7 (14.0%)       |    |         |
| Patients with an MBD inpatient admission, n (%) |                  |                  |    |         |
| Pre  | 3 (6.1%)              | 2 (4.0%)        | -0.28 | 0.92   |
| Post | 6 (12.2%)             | 5 (10.0%)       |    |         |
| Patients with an MBD ED visit, n (%) |                  |                  |    |         |
| Pre  | 11 (22.4%)            | 4 (8.0%)        | -4.05 | 0.04   |
| Post | 5 (10.2%)             | 5 (10.0%)       |    |         |
| Patients with 2 or more acute encounters |                  |                  |    |         |
| Pre | 15 (30.6%)            | 17 (34.0%)      | 0.99 | 0.20   |
| Post | 20 (40.8%)            | 15 (30.0%)      |    |         |
| 30-day readmission (including OSH) |                  |                  |    |         |
| Pre | 4 (8.2%)              | 10 (20.0%)      | -1.07 | 0.10   |
| Post | 8 (16.7%)             | 8 (16.7%)       |    |         |
| OR, p value |                  |                  |    |         |
| Intervention (n = 46) | 32 (69.6%)          | 31 (64.6%)      | -0.69 | 0.32   |
| Control (n = 48) | 29 (63.0%)            | 33 (68.8%)      |    |         |
| Patients with an acute encounter, n (%) |                  |                  |    |         |
| Pre  | 36 (78.3%)            | 36 (75.0%)      | -1.66 | 0.40   |
| Post | 30 (65.2%)            | 34 (70.8%)      |    |         |
| OR, p value |                  |                  |    |         |
| Intervention (n = 95) | 66 (69.5%)          | 59 (60.2%)      | -0.79 | 0.11   |
| Control (n = 98) | 56 (58.9%)            | 62 (63.3%)      |    |         |
| Pre, including OSH | 56 (58.9%)          | 62 (63.3%)      | -0.50 | 0.28   |
| Post, including OSH | 42 (44.2%)          | 45 (45.9%)      |    |         |
| Pre, including OSH | 30 (31.6%)          | 32 (32.7%)      | -0.26 | 0.57   |
| Post, including OSH | 36 (37.9%)          | 43 (43.9%)      |    |         |

Pre, 6-month period prior to study enrollment, not including the encounter during which enrollment took place; post, 6 months after study enrollment, not including enrollment encounter. Acute encounter, ED visits + inpatient admissions. MBD, AHRQ’s “Mental, behavioral and neurodevelopmental disorders” category for primary diagnosis. OSH, outside hospitals; patient consent for collection of this data was only obtained for study 2, and billing codes were not available for these encounters. OR, odds ratio.
Table 3 Acute Care Utilization Measured as Numerical Counts of Events

| Study 1 | Study 2 | Combined |
|---------|---------|----------|
|         | Intervention \( (n = 49) \) | Control \( (n = 50) \) | OR | \( p \) value | Intervention \( (n = 48) \) | Control \( (n = 48) \) | OR | \( p \) value | Intervention \( (n = 95) \) | Control \( (n = 98) \) | OR | \( p \) value |
| Number of acute encounters, mean \( (± SD) \) | | | | | | | | | | | | |
| Pre | 1.63 \( (± 2.55) \) | 1.36 \( (± 1.85) \) | 0.17 | 0.68 | 2.43 \( (± 3.40) \) | 2.52 \( (± 3.74) \) | -0.51 | 0.31 | 2.02 \( (± 3.00) \) | 1.93 \( (± 2.97) \) | -0.16 | 0.61 |
| Post | 1.90 \( (± 2.84) \) | 1.46 \( (± 2.15) \) | 2.11 \( (± 3.12) \) | 2.71 \( (± 3.50) \) | 3.20 \( (± 4.16) \) | 4.13 \( (± 5.89) \) | -0.08 | 0.92 | 2.00 \( (± 2.96) \) | 2.07 \( (± 2.94) \) | 0.07 | 0.73 |
| Pre, including OSH | | | | | | | | | | | | |
| Post, including OSH | | | | | | | | | | | | |
| Number of inpatient admissions, mean \( (± SD) \) | | | | | | | | | | | | |
| Pre | 0.39 \( (± 1.02) \) | 0.66 \( (± 1.72) \) | 0.03 | 0.46 | 0.83 \( (± 1.48) \) | 0.65 \( (± 1.39) \) | -0.14 | 0.66 | 0.60 \( (± 1.28) \) | 0.68 \( (± 1.41) \) | 0.07 | 0.73 |
| Post | 0.63 \( (± 1.20) \) | 0.07 \( (± 0.77) \) | 0.93 \( (± 1.53) \) | 0.90 \( (± 1.28) \) | 0.87 \( (± 1.56) \) | 0.94 \( (± 1.63) \) | 0.05 | 0.89 | 0.78 \( (± 1.37) \) | 0.80 \( (± 1.27) \) | 0.11 | 0.86 |
| Pre, including OSH | | | | | | | | | | | | |
| Post, including OSH | | | | | | | | | | | | |
| Number of ED visits, mean \( (± SD) \) | | | | | | | | | | | | |
| Pre | 1.24 \( (± 1.93) \) | 0.74 | -0.10 | 0.74 | 2.01 | 1.88 | 0.37 | 0.11 | 1.42 | 1.24 | 0.23 | 0.39 |
| Post | 1.27 \( (± 2.14) \) | 0.75 | 0.17 | 1.81 | 1.25 | 1.28 | 0.22 | 0.38 | 1.22 | 1.21 | 0.39 | 0.39 |
| Pre, including OSH | | | | | | | | | | | | |
| Post, including OSH | | | | | | | | | | | | |
| Number of MBD acute encounters, mean \( (± SD) \) | | | | | | | | | | | | |
| Pre | 0.37 \( (± 0.81) \) | 0.16 | -0.08 | 0.66 | 0.43 | 0.24 | -0.31 | 0.15 | 0.40 | 0.40 | -0.19 | 0.17 |
| Post | 0.39 \( (± 1.27) \) | 0.26 | 0.41 | 0.96 | 0.41 | 0.96 | -0.31 | 0.15 | 0.40 | 0.60 | 0.19 | 0.17 |
| Number of MBD inpatient admissions, mean \( (± SD) \) | | | | | | | | | | | | |
| Pre | 0.08 \( (± 0.34) \) | 0.06 | 0.06 | 0.48 | 0.09 | 0.29 | 0.02 | 0.81 | 0.08 | 0.12 | 0.04 | 0.51 |
| Post | 0.18 \( (± 0.57) \) | 0.10 | 0.25 | 0.60 | 0.17 | 0.49 | 0.18 | 0.53 | 0.17 | 0.48 | 0.04 | 0.51 |
| Number of MBD ED visits, mean \( (± SD) \) | | | | | | | | | | | | |
| Pre | 0.29 \( (± 0.61) \) | 0.10 | -0.14 | 0.31 | 0.35 | 0.11 | -0.34 | 0.12 | 0.32 | 0.29 | -0.24 | 0.06 |
| Post | 0.20 \( (± 0.79) \) | 0.16 | 0.24 | 0.95 | 0.71 | 1.81 | 0.22 | 0.87 | 0.43 | 1.35 | | |

All encounter count frequencies were right-skewed with median 0. Pre, the 6-month time period prior to the date of study enrollment, not including the encounter during which enrollment took place; post, the 6-month time period after the date of study enrollment, not including the enrollment encounter. Acute encounter, ED visits + inpatient admissions. MBD, AHRQ's "Mental, behavioral and neurodevelopmental disorders" category for primary diagnosis. OSH, outside hospitals; patient consent for collection of this data was only obtained for study 2, and billing codes were not available for these encounters. OR, odds ratio
despite these effects, the combined study results still show a significant decrease in MBD ED visits.

Although there were positive findings on MBD ED visits, the PRC intervention did not significantly impact overall utilization, inpatient utilization, or 30-day readmission. In contrast to these PRC intervention results, a recent RCT evaluating navigation services by master’s-level social workers on 282 hospitalized patients with SUD in Baltimore, MD, found significant reductions in subsequent ED visits, inpatient admissions, and 30-day readmissions.\(^\text{34}\) Despite a similar population, the control readmission rate in the Baltimore study was nearly double that of the current study (30.0% vs 17.3%, respectively) while the intervention readmission rates were similar (15.5% vs 15.8%, respectively). The Baltimore study excluded methamphetamine-predominant SUD, recent suicide attempt, and discharge to long-term care facility. The predominant SUD type in the Baltimore study was any opioid (78.5%), whereas the substances of the current study had even distribution between any opioid (36.3%) and any methamphetamines (32.1%). Opioid use disorder has more effective treatment options (i.e., buprenorphine/methadone) than methamphetamines, and the Baltimore site had an inpatient addiction service on which to layer the additional social work services.

Another recent study in Camden, NJ, evaluated the effect of a team of nurses, social workers, and community health workers on 800 inpatients with at least 1 prior hospitalization in the preceding 6 months, 44% of whom had comorbid SUD.\(^\text{35}\) The intervention provided no significant change in any readmission interval through 365 days, including the 30-day readmission rate (30.6%) despite being much larger than the current study and the Baltimore study, providing a high-intensity intervention, and starting with a high baseline readmission rate.

Given that this study did find a significant decrease in MBD-related ED visits, it is possible that these interventions may be more effective in decreasing acute care visits for lower severity, SUD-related complaints which were best demonstrated in the Baltimore study and diluted by more medical-related acute care visits in the Camden study.

This study had several limitations. Size was relatively small. Heterogeneity in substance type, pre-enrollment utilization, and severity of illness reflected real-world practice but contributed to imprecision. Interim analysis was performed between study 1 and study 2; this possible source of bias was accounted for by including data from both studies separately as well as combined.

Study 1 did not include information regarding outside hospital utilization; this was addressed by adding limited outside records review to the consent process for study 2: adding information from surrounding hospitals in study 2 did not change the primary outcomes, but billing data was unavailable for subgrouping by primary diagnosis code. Due to this data limitation, the significant finding in this study was only able to be observed in a single hospital system.

Patients in the control group were invited to establish care with a PRC on their own initiative which risked diluting the observed effect of the PRC: however, only 2 patients in study 1, and 0 patients in study 2, did so.

In conclusion, a PRC intervention for inpatients with SUD did not decrease overall acute care utilization but may decrease MBD-related ED visits. This contributes to an overall mixed picture in the literature evaluating the effect of social support interventions on acute care utilization.

**Acknowledgements:** This work was supported through the Health Sciences Center at Prisma Health Transformative Research Seed Grant Award and the Prisma Health-Upstate Addiction Research Center.

**Corresponding Author:** Julia A. Cupp, MD; Prisma Health-Upstate, Greenville, USA (e-mail: Julia.Cupp@PrismaHealth.org).

**Funding** Prisma Health Transformative Research Seed Grant.
Declarations:

Conflict of Interest: The authors declare that they do not have a conflict of interest.

REFERENCES

1. Lever D, Freer J, King E, et al. Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. Addiction. 2019;115:1011–1023. https://doi.org/10.1111/add.14892

2. Walley A, Paasche-Orlow M, Lee E, et al. Acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis. J Addict Med. 2012;6(1):50-56. doi:10.1097/ADM.0b013e318231de51

3. Moe J, Kirkland SW, Rawe E, et al. Effectiveness of interventions to decrease emergency department visits by adult frequent users: a systematic review. Acad Emerg Med. 2017;24(1):40-52. https://doi.org/10.1111/acem.13060

4. Bodenheimer T. Strategies to reduce costs and improve care for high-utilizers: 10 year economic reflections on pioneering programs.; 2013. http://www.ches.org/media/HighUtilizerReport_105413_Final43.pdf

5. Hong CS, Siegel AL, Ferris TG. Caring for high-need, high-cost patients: what makes for a successful care management program? Commonw Fund. 2014;19(August):1-19. https://doi.org/10.1016/j.trac.2015.07.006

6. Kirk TA, Di Leo P, Rehmer P, Moy S, Davidson L. A case and care management program to reduce use of acute care by clients with substance use disorders. Psychiatr Serv. 2013;64(5):491-493. https://doi.org/10.1176/appi.ps.201200258

7. Chakravarty S, Cantor JC. Informing the design and evaluation of superuser care management initiatives. Med Care. 2016;54(9):860-867. https://doi.org/10.1097/MLR.0000000000000566

8. Williams BC. Limited effects of case management for high utilizer on total healthcare costs. Am J Manag Care. 2015;21(4):244-246.

9. Raven MC, Kushel M, Ko MJ, Penko J, Bindman AB. The effectiveness of emergency department visit reduction programs: a systematic review. Ann Emerg Med. 2016;68(4):467-483.e15. https://doi.org/10.1016/j.annemergmed.2016.04.015

10. Edgren G, Anderson J, Dolk A, et al. A case management intervention targeted to reduce healthcare consumption for frequent Emergency Department visitors: results from an adaptive randomized trial. Eur J Emerg Med. 2016;23(5):344-350. https://doi.org/10.1097/MED.0000000000000280

11. Lin MP, Blanchfield BB, Kakozza RM, et al. ED-based care coordination reduces costs for frequent ED users. Am J Manag Care. 2017;23(12):762-766. www.ajmc.com. Accessed March 28, 2021.

12. Bodenmann P, Velonaki VS, Griffin JL, et al. Case management may reduce emergency department frequent use in a universal health care coverage system: a randomized controlled trial. J Gen Intern Med. 2017;32(5):508-515. https://doi.org/10.1007/s11606-017-3879-9

13. Post B, Lapedis J, Singh K, et al. Predictive model-driven hotpotting to decrease emergency department visits: a randomized controlled trial. J Gen Intern Med. 2021;36(9):2563-2570. https://doi.org/10.1007/s11606-021-06664-1

14. Tait RJ, Teoh L, Kelty E, Geelhoed E, Mountain D, Hulse GK. Emergency department based intervention with adolescent substance users: 10 year economic and health outcomes. Drug Alcohol Depend. 2016;165:168-174. https://doi.org/10.1016/j.drugalcdep.2016.06.005

15. Stergioulas V, Godzik A, Cohen A, et al. The effect of brief case management on emergency department use of frequent users in mental health: Findings of a randomized controlled trial. PLoS One. 2017;12(8). https://doi.org/10.1371/journal.pone.0182157

16. McLaughlin-Davis M. The practice of hospital case management: a white paper. Prof Case Manag. 2019;24(5):280-296. https://doi.org/10.1097/NCM.0000000000000391

17. Hesse M, Vanderplasschen W, Rapp R, Broekaert E, Fridell M. Case management for persons with substance use disorders (Review).

Cochrane Database Syst Rev. 2007;(4). https://doi.org/10.1002/14651858.CD006265.pub2 www.cochranelibrary.com

18. Rapp RC, Van Den Noortgate W, Broekaert E, Vanderplasschen W. The efficacy of case management with persons who have substance abuse problems: a three-level meta-analysis of outcomes. J Consult Clin Psychol. 2014;82(4):605-618. https://doi.org/10.1037/a0036750

19. Joo JY, Huber DL. Community-based case management effectiveness in populations that abuse substances. Int Nurs Rev. 2015;62(4):536-546. https://doi.org/10.1111/inr.12201

20. Vanderplasschen W, Rapp RC, De Maeyer J, Van Den Noortgate W. A meta-analysis of the efficacy of case management for substance use disorders: a recovery perspective. Front Psychiatry. 2019;10:186. https://doi.org/10.3389/fpsyt.2019.00116

21. Penzenstadler L, Machado A, Thorens G, Zullino D, Khazaal Y. Effect of case management interventions for patients with substance use disorders: a systematic review. Front Psychiatry. 2017;8(APR). https://doi.org/10.3389/fpsyt.2017.00651

22. Comprehensive Case Management for Substance Abuse Treatment. Rockville (MD): 2000.

23. Eddie D, Hoffman L, Vilain C, et al. Lived experience in new models of care for substance use disorder: a systematic review of peer recovery support services and recovery coaching. Front Psychol. 2019;10(JUN). https://doi.org/10.3389/fpsyg.2019.01052

24. Liebling EJ, Perez JJS, Litterer MM, et al. Implementing hospital-based peer recovery support services for substance use disorder disorder. Am J Drug Alcohol Abuse. 2021;47(2):229-237. https://doi.org/10.1080/00952990.2020.1841218

25. NAADAC, National Certified Peer Recovery Support Specialist (NCPRSS). www.naadac.org/nccrps. Published 2021. Accessed September 26, 2021.

26. Bassuk EL, Hanson J, Greene RN, Richard M, Laudet A. Peer-delivered recovery support services for addictions in the united states: a systematic review. J Subst Abuse Treat. 2016;63:1-9. https://doi.org/10.1016/j.jsat.2016.01.003

27. Byrne KA, Roth PJ, Merchant K, et al. Inpatient link to peer recovery coaching: results from a pilot randomized control trial. Drug Alcohol Depend. 2020;215(june):108234. https://doi.org/10.1016/j.drugalcdep.2020.108234

28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodol-ogy and workflow process for providing translational research informat-sions. J Biomed Inform. 2009;42(2):377-381. https://doi.org/10.1016/j.jbi.2008.08.010

29. van Walraven C, Wong J, Forster AJ. LACE+ index: extension of a validated index to predict early death or urgent readmission after hospital discharge using administrative data. Open Med. 2012;6(2):1-11.

30. Clinical Classifications Software Refined (CCSR) for ICD-10-CM Diagnosis. https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/dxccsr.jsp. Accessed March 28, 2021.

31. Shumway M, Boccelli A, O’Brien K, Okin RL. Cost-effectiveness of clinical case management for ED frequent users: results of a randomized triallist, open. Am J Manag Care. 2005;20(12):155-164. https://doi.org/10.1016/j.ajmc.2007.04.021

32. Shah, R, Chen C, O’Rourke S, Lee M, Mohanthy SA, Abraham J. Evaluation of care management for the uninsured. Med Care. 2011;49(2):166-171. https://doi.org/10.1097/MLR.0b013e318079307-x

33. Hartnett K, Kite-Powell A, Devies J, et al. Impact of the COVID-19 pandemic on emergency department visits — United States, January 1, 2019-May 30, 2020. Morb Mortal Wkly Rep. 2020;69(23):689-704.

34. Gryczynski J, Nordeck CD, Welsh C, Mitchell SG, O’Grady KE, Schwartz RP. Preventing hospital readmission for patients with concomit substace use disorder. Ann Intern Med. 2021. https://doi.org/10.7326/m20-5475

35. Finkelstein A, Zhou A, Taubman S, Doyle J. Health care hotspotting — a randomized, controlled trial. N Engl J Med. 2020;382(22):152-162. https://doi.org/10.1056/NEJMsa1906848

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.